Crystal's MCW Coder Hub🧬 ICD-10-CM H40.63X2 — Glaucoma Secondary to Drugs, Bilateral, Moderate Stage
Billable Code Confirmed — 7 Characters Complete
ICD-10 CM H40.63X2 is a valid, billable 7-character ICD-10-CM code for FY2025. Structure:
H40(glaucoma) +.6(secondary to drugs) +3(bilateral) +X(structural placeholder) +2(moderate stage). Complete and current.
Non-Billable Parent Codes — Do Not Submit
- ❌
H40.63— 5-character header — non-billable- ❌
H40.6— 4-character header — non-billable
🚨 MANDATORY ADDITIONAL CODE — T-Code Required
Cross-Reference
For full pathophysiology, staging deep-dive, T-code mechanics, steroid background, and CPT templates → H40.61X2 (right eye moderate). This note focuses on the bilateral code — WHEN it applies, when it does NOT, and the ICD-10-CM guideline that governs it.
🔍 Code Description
H40.63X2 classifies glaucoma secondary to drug therapy, affecting both eyes, at the moderate stage — bilateral drug-induced glaucomatous optic neuropathy in which both the right and left eyes have a Humphrey Visual Field 24-2 mean deviation between -6 dB and -12 dB, with field loss outside the central 5° of fixation in both eyes. The bilateral code is a single-code shorthand for symmetric bilateral disease — it replaces the need to report H40.61X2 and H40.62X2 separately when both eyes are confirmed at identical type and stage.
The key word is identical. The moment one eye diverges — different stage, different type, or one eye normal — the bilateral code no longer applies and laterality-specific codes take over. Understanding when to use H40.63X2 versus the laterality pair is one of the most tested ICD-10-CM glaucoma guideline concepts in ophthalmic coding certification.
🔑 The Bilateral Code Rule — ICD-10-CM Guideline Section I.C.7
This is CIC exam material. ICD-10-CM has explicit guidelines for bilateral glaucoma coding that govern when H40.63X2 is appropriate versus when separate laterality codes are required.
The Four Bilateral Glaucoma Guideline Scenarios
Scenario A — Same Type, Same Stage, Bilateral Code Exists → USE BILATERAL CODE ✅
Use H40.63X2 — both eyes same type (secondary to drugs) + same stage (moderate) + bilateral code exists in classification
Both eyes: drug-induced glaucoma, both moderate → H40.63X2 alone + T-code
Scenario B — Same Type, DIFFERENT Stage → USE SEPARATE LATERALITY CODES ❌ No Bilateral
Do NOT use H40.63X2 when stages differ between eyes
| Right Eye | Left Eye | Correct Coding |
|---|---|---|
| Mild H40.61X1 | Moderate H40.62X2 | Two separate codes — stages differ |
| Moderate H40.61X2 | Severe H40.62X3 | Two separate codes — stages differ |
| Indeterminate H40.61X4 | Moderate H40.62X2 | Two separate codes — stages differ |
| Moderate H40.61X2 | Moderate H40.62X2 | H40.63X2 — same stage ✅ |
Scenario C — DIFFERENT Types, No Bilateral Code for Mixed Type → SEPARATE CODES
When one eye has drug-induced glaucoma and the other has a different type (e.g., primary open-angle), each is coded separately with its own laterality-specific code
Right: H40.61X2 (secondary to drugs, moderate) + Left: H40.1122 (POAG, left, moderate) → two codes, no bilateral
Scenario D — Same Type, Same Stage, NO Bilateral Code Exists → ONE CODE, ONE ENTRY
For glaucoma types where ICD-10-CM does not provide a bilateral code (e.g., H40.10, H40.20 — unspecified open-angle, primary angle-closure), report only ONE code for the type with the 7th character for the stage — do not repeat the code
H40.6x does provide a bilateral code (H40.63x) — so this scenario does not apply here. Always use H40.63X2 when both eyes qualify. [web:256]
The One-Line Decision Rule for H40.63X2
🌳 The Full H40.6x Bilateral Family in Context
H40.6 Glaucoma Secondary to Drugs ❌ Non-billable
│
├── H40.60 Unspecified eye ❌ Non-billable header
│
├── H40.61 Right eye ❌ Non-billable header
│ ├── H40.61X1 Mild
│ ├── H40.61X2 Moderate
│ ├── H40.61X3 Severe
│ └── H40.61X4 Indeterminate
│
├── H40.62 Left eye ❌ Non-billable header
│ ├── H40.62X1 Mild
│ ├── H40.62X2 Moderate
│ ├── H40.62X3 Severe
│ └── H40.62X4 Indeterminate
│
└── H40.63 BILATERAL ❌ Non-billable header
├── H40.63X0 Stage unspecified ⚠️
├── H40.63X1 Mild bilateral
├── H40.63X2 MODERATE bilateral ← THIS CODE ✅
├── H40.63X3 Severe bilateral
└── H40.63X4 Indeterminate bilateral
📊 When H40.63X2 Applies vs. When It Does Not — Decision Matrix
| Clinical Scenario | Right Eye | Left Eye | Code |
|---|---|---|---|
| ✅ Both eyes moderate, same drug | Moderate | Moderate | H40.63X2 |
| ❌ Asymmetric — mild/moderate | Mild | Moderate | H40.61X1 + H40.62X2 |
| ❌ Asymmetric — moderate/severe | Moderate | Severe | H40.61X2 + H40.62X3 |
| ❌ Right eye only | Moderate | Normal/no glaucoma | H40.61X2 only |
| ❌ Different glaucoma types | Drug-induced moderate | POAG moderate | H40.61X2 + H40.1122 |
| ❌ Both moderate but one indeterminate | Indeterminate | Moderate | H40.61X4 + H40.62X2 |
| ⚠️ Both unspecified — query | Unspecified | Unspecified | H40.63X0 — then CDI query |
🔬 Bilateral SIG — Clinical Profile at Moderate Stage
Drug-induced glaucoma, particularly steroid-induced, has a uniquely symmetric bilateral presentation compared to primary open-angle glaucoma — because the steroid exposure typically affects both eyes simultaneously and proportionally. This is the most common clinical scenario driving H40.63X2 use:
Why Bilateral SIG Tends to Be Symmetric
| Reason | Clinical Impact |
|---|---|
| Systemic steroids (oral/IV) | Identical drug exposure both eyes — IOP rise and glaucomatous damage progress at the same rate |
| Bilateral intravitreal injections | Both eyes receiving Ozurdex or triamcinolone on similar schedules — parallel IOP trajectories |
| Inhaled/intranasal steroids | Systemic absorption affects both eyes equally |
| Topical steroids applied bilaterally | Both eyes exposed equally — symmetric response |
Topical Steroids Applied to ONE Eye Only → May Be Asymmetric
When a topical steroid is applied only to the right eye (e.g., for post-op inflammation OD only), the IOP rise and subsequent glaucoma develops unilaterally — use H40.61X2 (right eye only), not the bilateral code. The bilateral code requires bilateral drug exposure producing bilateral disease.
Bilateral Moderate Stage — What Both Eyes Show
| Finding | Both Eyes at H40.63X2 |
|---|---|
| HVF OD | MD -6 to -12 dB — arcuate defect, nasal step, or paracentral loss |
| HVF OS | MD -6 to -12 dB — similar pattern |
| OCT RNFL OD | Moderate thinning — superior and/or inferior sectors |
| OCT RNFL OS | Moderate thinning — same or mirror pattern |
| C/D ratio | Enlarged OU — typically 0.6-0.8 |
| Central VA | Preserved OU — 20/20 to 20/40 |
| IOP | May or may not be elevated at monitoring visit — depends on treatment response |
💊 CPT Templates — Bilateral Testing at H40.63X2
Bilateral CPT Billing — Modifier Strategy
H40.63X2 is a bilateral diagnosis code — both eyes are diseased. CPT codes for testing and procedures performed on both eyes are handled differently than unilateral codes. Modifier strategy:
CPT Bilateral Approach Notes 92083 — HVF No modifier — test covers both eyes in one unit Standard bilateral VF test — one unit, both eyes 92133 — OCT RNFL -50 modifier (bilateral) OR -RT + -LT two lines Payer-dependent — verify preferred billing method 92014 — Exam No modifier — comprehensive exam is inherently bilateral 65855 — SLT -50 modifier OR two line items -RT + -LT Only if SLT performed both eyes same DOS 66170/66172 — Trabeculectomy Two separate line items -RT and -LT Bilateral filtering surgery — typically staged, not same DOS
Template A: Bilateral Monitoring Visit — Both Eyes Moderate, Established Patient
| Code | Modifier | Description | Notes |
|---|---|---|---|
| 92014 | — | Comprehensive exam, established | Full bilateral exam |
| 92083 | — | HVF 24-2 bilateral | Documents bilateral MD -6 to -12 dB |
| 92133 | -50 | OCT RNFL bilateral | Bilateral RNFL thinning — payer may prefer -RT/-LT |
| H40.63X2 | Primary Dx | Bilateral moderate stage ← single code covers both eyes | |
| T38.0X5D | Required additional | One T-code covers both eyes |
Template B: Bilateral SLT — Both Eyes Same Visit
Uncommon to perform SLT bilaterally on the same day, but not prohibited. Verify payer authorization.
| Code | Modifier | Description |
|---|---|---|
| 92014 | — | Pre-procedure exam |
| 65855 | -RT | SLT right eye |
| 65855 | -LT | SLT left eye |
| H40.63X2 | Primary Dx | |
| T38.0X5D | Required additional |
💊 Coding Scenarios
Scenario 1 — Classic Bilateral Symmetric SIG, Both Eyes Moderate (Use Bilateral Code ✅)
Clinical Vignette: A 67-year-old male with bilateral steroid-induced glaucoma from chronic oral prednisone for polymyalgia rheumatica presents for 4-month monitoring. IOP: OD 17 mmHg, OS 18 mmHg on bilateral latanoprost + dorzolamide/timolol. HVF 24-2: OD MD -7.3 dB (moderate), OS MD -8.8 dB (moderate). Both fields outside 5° of fixation. OCT RNFL: moderate superior/inferior thinning OU. Physician: “Bilateral steroid-induced glaucoma, moderate stage — symmetric. Continue current drops. Discussing SLT OU at next visit.”
ICD-10-CM:
- H40.63X2 — Glaucoma secondary to drugs, bilateral, moderate stage (both eyes same type, same stage — bilateral code applies)
- T38.0X5D — Adverse effect of glucocorticoids, subsequent encounter
- M35.3 — Polymyalgia rheumatica (underlying condition requiring prednisone)
One Code Does the Work of Two Here
Scenario 2 — One Eye Progresses — Code Changes Mid-Care
Visit 1: Both eyes moderate SIG — H40.63X2 appropriate.
Visit 2 (6 months later): Right eye HVF: MD -13.2 dB — PROGRESSED to severe. Left eye HVF: MD -8.4 dB — still moderate. Physician: “Right eye progressed to severe stage — left eye stable at moderate.”
Visit 2 ICD-10-CM — Bilateral Code RETIRED:
- H40.61X3 — Right eye, severe (progressed from moderate — stages now differ)
- H40.62X2 — Left eye, moderate (stable — still moderate)
- T38.0X5D — Adverse effect, subsequent encounter
Retire H40.63X2 the Moment Stages Diverge
H40.63X2 is no longer valid once the two eyes are at different stages. The moment one eye progresses (or regresses) to a different stage than the other, the bilateral code must be replaced with two laterality-specific codes documenting each eye’s current confirmed stage. [web:255][web:256] This code change should occur at the encounter where the new stage is first documented — not retroactively.
Scenario 3 — Both Eyes Moderate But One Indeterminate — Do NOT Use Bilateral ❌
Clinical Vignette: A 74-year-old female with bilateral SIG secondary to inhaled fluticasone. Left eye: HVF OS MD -9.1 dB — moderate, reliable. Right eye: HVF OD attempted — unreliable (fixation losses 31%) due to dense PSC OD. OCT OD: moderate-advanced thinning. Physician: “Left eye moderate stage confirmed. Right eye — cannot stage due to unreliable VF — indeterminate. Planning cataract surgery OD.”
ICD-10-CM — Do NOT use H40.63X2:
- H40.61X4 — Right eye, indeterminate (cannot stage — PSC blocking reliable VF)
- H40.62X2 — Left eye, moderate (confirmed MD -9.1 dB)
- T38.0X5D — Adverse effect, subsequent encounter
- H26.13 — Posterior subcapsular cataract OD (staging barrier)
Indeterminate ≠ Moderate — Never Bundle Into Bilateral Code
Even when the physician suspects both eyes are at a similar stage, if one eye is indeterminate (H40.61X4) because reliable testing is unavailable, that eye CANNOT be assumed to be moderate. The bilateral code H40.63X2 requires confirmed moderate stage in both eyes. Suspicion or inference is not sufficient — document what is confirmed and code accordingly.
⚠️ Full H40.6x Drug-Induced Glaucoma — Complete Bilateral Picture
| Bilateral Code | Stage | Both Eyes Confirmed At | Replaces |
|---|---|---|---|
| H40.63X0 | Unspecified | Neither eye staged | Both H40.61X0 + H40.62X0 ⚠️ |
| H40.63X1 | Mild | Both MD > -6 dB | H40.61X1 + H40.62X1 |
| H40.63X2 | Moderate | Both MD -6 to -12 dB | H40.61X2 + H40.62X2 |
| H40.63X3 | Severe | Both MD < -12 dB | H40.61X3 + H40.62X3 |
| H40.63X4 | Indeterminate | Both cannot be staged | H40.61X4 + H40.62X4 |
🔗 Related ICD-10-CM Codes
| Code | Description | Relationship |
|---|---|---|
| H40.61X2 | Right eye, moderate | Right-eye laterality version |
| H40.62X2 | Left eye, moderate | Left-eye laterality version |
| H40.63X1 | Bilateral, mild | Earlier stage — both eyes improved or early |
| H40.63X3 | Bilateral, severe | Later stage — both eyes progressed |
| H40.63X4 | Bilateral, indeterminate | Both eyes cannot be staged |
| T38.0X5D | Adverse effect glucocorticoids, subsequent | Mandatory T-code |
| H26.13 | PSC cataract | Common steroid comorbidity |
| Z79.52 | Long-term systemic steroid use | Chronic exposure documentation |
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never use H40.63X2 when stages differ between eyes — it requires confirmed same stage in both eyes; asymmetric staging → two laterality-specific codes |
| ❌ | Never submit H40.63X2 without T38.0X5x — mandatory regardless of laterality |
| ❌ | Never use H40.63X2 when different glaucoma types affect each eye — bilateral code only for same type AND same stage |
| ❌ | Never assume bilateral when only one eye is documented — both eyes must have confirmed drug-induced glaucoma |
| ❌ | Never keep H40.63X2 after one eye progresses to a different stage — retire bilateral code; assign separate laterality codes |
| ✅ | Three-check rule before assigning: same type ✅ + same stage ✅ + bilateral code exists ✅ |
| ✅ | One T-code covers both eyes — T38.0X5D listed once, covers bilateral disease from same drug |
| ✅ | No CPT modifier on H40.63X2 itself — it IS the bilateral code; modifiers go on the CPT procedures |
| ✅ | Retire immediately when stages diverge — code change happens at the encounter where progression is first documented |
| ✅ | CMS LCD A56916 explicitly lists H40.63X2 as covered Dx for 92133 OCT |
| ✅ | CMS LCD A56799 confirms H40.63X1-X4 as covered for visual fields testing |
| ✅ | Bilateral SIG from systemic steroids is the most common real-world trigger for H40.63X2 — oral prednisone, methylprednisolone, inhaled corticosteroids affect both eyes equally |
📚 Sources
1. AAPC. ICD-10-CM Code H40.63 — Glaucoma secondary to drugs, bilateral. T-code use additional code instruction confirmed. H40.63 confirmed non-billable header; H40.63X2 confirmed billable. [web:251]
2. Unbound Medicine ICD-10-CM. “H40.63 — Glaucoma secondary to drugs, bilateral [Non-Billable].” Full stage family confirmed — H40.63X0 through H40.63X4. H40.63X2 listed. [web:253]
3. CMS LCD Article A56916 — SCODI. “H40.63X2 — Glaucoma secondary to drugs, bilateral, moderate stage” explicitly listed as covered diagnosis for CPT 92133. [web:54]
4. CMS LCD Article A56799 — Visual Fields Testing. “H40.63X1-H40.63X4” confirmed as covered diagnoses for visual field testing. [web:258]
5. Outsource Strategies International. “Coding Guidelines for Glaucoma.” ICD-10-CM bilateral glaucoma rule: “When a patient has bilateral glaucoma and both eyes are documented as having the same type and stage, only report the specific bilateral glaucoma code.” [web:255]
6. IKS Health. “Coding Glaucoma.” March 2025. Full four-scenario bilateral guideline framework confirmed — same type/same stage → bilateral; different stages → separate laterality codes; no bilateral code exists → one code for both. [web:256]
7. Coding Billing Solutions. “Glaucoma ICD-10 Codes.” Full H40.63 bilateral family structure confirmed including H40.63X2. [web:199]
8. See H40.61X2 for complete citation list covering pathophysiology, staging criteria, T-code framework, and CPT billing detail.